반려동물 백신 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the companion animal vaccine market size is projected to expand from USD 3.80 billion in 2025 and USD 4.03 billion in 2026 to USD 5.40 billion by 2031, registering a CAGR of 6.02% between 2026 to 2031.

This report is Segmented by Technology (Live Attenuated, Inactivated, and More), Animal Type (Dogs, Cats, and Other Companion Animals), Disease Indication (Rabies, and More), End-User (Veterinary Hospitals & Clinics, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Companion Animal Vaccine Market Trends and Insights

Rising Adoption of Companion Animals Globally

China counted 187 million dogs and cats in 2024, and India's dog population climbed from 19.4 million in 2018 to 31 million by 2023, creating a durable base for routine immunization. Similar gains appeared in the United States, where the American Veterinary Medical Association (AVMA) recorded 89.7 million dogs and 73.8 million cats in households during 2024. Shelter adoptions advanced 12% year-over-year, and updated intake guidelines require vaccination within 48 hours, which boosts immediate demand for rapid-onset formulations. Urbanization elevates disposable income, allowing owners to treat pets as family and prioritize preventive care, including combination boosters. Manufacturers have responded with single-dose, high-titer vials that appeal to first-time owners seeking convenience.

Increasing Incidence of Zoonotic Diseases and Public Health Campaigns

Roughly 60% of emerging human pathogens are zoonotic, a statistic that underpins the CDC-WHO One Health framework. Rabies caused an estimated 59,000 human deaths in 2024, with dogs responsible for 99% of transmission, propelling the WHO Zero by 30 campaign. In the United States, leptospirosis cases in dogs rose 18% between 2020 and 2024, prompting veterinary associations to reclassify the vaccine from optional to recommended in 32 states. New CDC import standards introduced in 2024 mandate rabies vaccination for dogs entering from high-risk countries, ensuring cross-border compliance.

High Cost of Vaccine Development and Regulatory Approvals

Bringing a new veterinary vaccine from discovery to USDA or FDA-CVM approval can require 5-7 years and USD 10-50 million, levels that deter smaller entrants. Mandatory efficacy studies in target species, pediatric safety assessments, and multi-temperature stability trials extend timelines compared with some human emergency pathways. Recombinant and mRNA constructs face extra scrutiny under GMO rules; Australia's three-year Nobivac Puppy DP Plus review included environmental assessments and public comments before clearance in 2024. Patent cliffs loom for blockbuster portfolios, such as those of Vanguard and Nobivac, yet generics remain scarce because replicating live attenuated master seeds under current Good Manufacturing Practice (cGMP) conditions is technically demanding.

Other drivers and restraints analyzed in the detailed report include:

1. Advancements in Vaccine Biotechnology Such as Recombinant Platforms
2. Government Rabies Elimination Initiatives Mandating Canine Vaccination
3. Cold-Chain and Distribution Challenges in Emerging Economies

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Live attenuated products held a 42.45% market share in the companion animal vaccines market in 2025, securing their role as cost-efficient options for core diseases such as distemper and parvovirus. The recombinant segment is projected to grow at an 8.43% CAGR from 2026 to 2031, driven by its safety edge, improved stability, and the newly validated regulatory path, as demonstrated by Australia's 2024 approval of Nobivac Puppy DP Plus. Inactivated platforms remain important for rabies and leptospirosis, but face price pressure as recombinant titers reach parity. Toxoid, viral vector, and virus-like particle technologies collectively represented roughly 8% of sales in 2025, while DNA and mRNA candidates are still in pre-commercial phases, despite showing encouraging antibody profiles in 2025 peer-reviewed trials.

Future growth will hinge on lowering production costs and simplifying cold-chain logistics. Recombinant subunits can be produced in lower-biosafety fermenters, reducing capital expenditures, and single-dose packaging streamlines clinic workflow. Manufacturers are also exploring needle-free injectors and intranasal formats to minimize stress on animals and owners, factors that could further lift adoption. As patent protection wanes for legacy attenuated brands, recombinant developers expect more expansive room for price-mix gains and faster uptake of novel constructs within the companion animal vaccines market.

Dogs generated 62.56% of 2025 revenue, mainly due to higher disease-coverage breadth and stricter rabies mandates. Nevertheless, the cat segment is forecasted to grow at an 8.65% CAGR through 2031, mirroring the shift toward apartment living and the widespread implementation of FVRCP protocols that require vaccination within two days of admission. Feline uptake also benefits from convenient combination vials that reduce the need for multiple clinic visits. Meanwhile, rabbits, birds, equines, and exotic pets together accounted for about 12% of spending in 2025, primarily tied to niche pathogens such as RHDV.

Guideline updates in 2024 reclassified FeLV from core to non-core for strictly indoor cats, temporarily reducing the vaccine's unit volumes while freeing budgets for newer feline immunodeficiency and infectious peritonitis candidates. In canine medicine, Lyme and leptospirosis boosters are climbing as tick and rodent ranges expand. Continued urbanization in the Asia-Pacific region is expected to keep the cat portfolio growing faster than the dog segment, thereby reinforcing its role in the companion animal vaccines market.

Complete Report Scope:

• By Technology
  • Live Attenuated Vaccines
  • Inactivated Vaccines
  • Toxoid Vaccines
  • Recombinant Vaccines
  • DNA & mRNA Vaccines
  • Other Technologies
• By Animal Type
  • Dogs
  • Cats
  • Other Companion Animals (Rabbits, Avian, Equine, Exotic)
• By Disease Indication
  • Rabies
  • Canine Distemper / Adenovirus / Parvovirus (DAPP)
  • Feline Panleukopenia / Herpes / Calicivirus (FVRCP)
  • Leptospirosis
  • Lyme Disease
  • Bordetella & Canine Parainfluenza
  • Other Disease Indications
• By End-User
  • Veterinary Hospitals & Clinics
  • Retail Pharmacies & Pet Stores
  • E-Commerce & Online Pharmacies
  • Animal Shelters & Rescue Organizations
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest Of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest Of Asia-Pacific
  • Middle East And Africa
    • GCC
    • South Africa
    • Rest Of Middle East And Africa
  • South America
    • Brazil
    • Argentina
    • Rest Of South America

Geography Analysis

North America maintained a 41.45% share of global volume in 2025, driven by high ownership rates and CDC regulations that consider rabies vaccination a compulsory public health measure. Canada's pet insurance coverage reached 4.5% in 2024, with 40% of policies covering preventive shots, a factor that translates into steadier order patterns. Corporate clinic chains dominate 25-30% of U.S. outlets, leveraging scale to pressure suppliers for rebates while still stocking premium recombinant brands.

Asia-Pacific is forecast for a 7.43% CAGR through 2031, buoyed by China's 187 million pets and India's aggressive rabies elimination budgets. Philippine approvals for Rabisin and Felocell-4 in 2024 broadened the catalogue for government procurement. Japan, South Korea, and Australia lead regional pet insurance uptake at 8-12%; these policies increasingly reimburse non-core vaccinations, nudging price mix higher.

Europe held roughly 28% of 2025 sales, aided by strict pet-travel rabies rules and EMA oversight that accelerates multi-antigen launches. The Middle East and Africa together captured 6%, with Kenya, Tanzania, and South Africa deploying USD 120 million in 2024 toward mass canine drives. South America represented 5%; Brazil and Argentina drive most volume, but face macroeconomic headwinds that slow the rollout of premium products. Cold-chain gaps persist in many rural areas, providing thermostable formulations with room to differentiate within the companion animal vaccines market.

1. Bayer
2. Bioveta
3. Boehringer Ingelheim
4. Bimeda Animal Health
5. Brilliant Bio Pharma
6. Ceva Sante Animale
7. Dechra Pharmaceuticals
8. Durvet
9. Elanco
10. Heska
11. Hester Biosciences
12. Hipra
13. IDT Biologika
14. Indian Immunologicals
15. Merck
16. Phibro Animal Health
17. Vaxxinova International
18. Vetoquinol
19. Virbac
20. Zoetis

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Adoption of Companion Animals Globally
  • 4.2.2 Increasing Incidence of Zoonotic Diseases and Public Health Campaigns
  • 4.2.3 Advancements in Vaccine Biotechnology Such as Recombinant Platforms
  • 4.2.4 Government Rabies Elimination Initiatives Mandating Canine Vaccination
  • 4.2.5 Shelter Intake Protocols Requiring Rapid-Onset Vaccines
  • 4.2.6 Pet Insurance Expansion Covering Preventive Vaccination Costs
• 4.3 Market Restraints
  • 4.3.1 High Cost of Vaccine Development and Regulatory Approvals
  • 4.3.2 Cold-Chain and Distribution Challenges in Emerging Economies
  • 4.3.3 Vaccine Hesitancy among Some Owners over Safety Concerns
  • 4.3.4 Consolidation of Veterinary Clinics Pressuring Pricing
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat Of New Entrants
  • 4.7.2 Bargaining Power Of Suppliers
  • 4.7.3 Bargaining Power Of Buyers
  • 4.7.4 Threat Of Substitute Products
  • 4.7.5 Intensity Of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Technology
  • 5.1.1 Live Attenuated Vaccines
  • 5.1.2 Inactivated Vaccines
  • 5.1.3 Toxoid Vaccines
  • 5.1.4 Recombinant Vaccines
  • 5.1.5 DNA & mRNA Vaccines
  • 5.1.6 Other Technologies
• 5.2 By Animal Type
  • 5.2.1 Dogs
  • 5.2.2 Cats
  • 5.2.3 Other Companion Animals (Rabbits, Avian, Equine, Exotic)
• 5.3 By Disease Indication
  • 5.3.1 Rabies
  • 5.3.2 Canine Distemper / Adenovirus / Parvovirus (DAPP)
  • 5.3.3 Feline Panleukopenia / Herpes / Calicivirus (FVRCP)
  • 5.3.4 Leptospirosis
  • 5.3.5 Lyme Disease
  • 5.3.6 Bordetella & Canine Parainfluenza
  • 5.3.7 Other Disease Indications
• 5.4 By End-User
  • 5.4.1 Veterinary Hospitals & Clinics
  • 5.4.2 Retail Pharmacies & Pet Stores
  • 5.4.3 E-Commerce & Online Pharmacies
  • 5.4.4 Animal Shelters & Rescue Organizations
• 5.5 Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest Of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest Of Asia-Pacific
  • 5.5.4 Middle East And Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest Of Middle East And Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest Of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials As Available, Strategic Information, Market Rank/Share For Key Companies, Products & Services, And Recent Developments)
  • 6.3.1 Bayer AG
  • 6.3.2 Bioveta AS
  • 6.3.3 Boehringer Ingelheim GmbH
  • 6.3.4 Bimeda Animal Health
  • 6.3.5 Brilliant Bio Pharma
  • 6.3.6 Ceva Sante Animale
  • 6.3.7 Dechra Pharmaceuticals PLC
  • 6.3.8 Durvet Inc.
  • 6.3.9 Elanco Animal Health Incorporated
  • 6.3.10 Heska Corporation
  • 6.3.11 Hester Biosciences Limited
  • 6.3.12 HIPRA
  • 6.3.13 IDT Biologika GmbH
  • 6.3.14 Indian Immunologicals Ltd
  • 6.3.15 Merck & Co. Inc.
  • 6.3.16 Phibro Animal Health Corporation
  • 6.3.17 Vaxxinova International
  • 6.3.18 Vetoquinol SA
  • 6.3.19 Virbac
  • 6.3.20 Zoetis Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-Space & Unmet-Need Assessment